We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Toward a broader concept of societal value: family spillovers in Alzheimer's disease.
- Authors
Park, Jenny Yeonhee; Marcum, Zachary A.; Garrison, Louis P.
- Abstract
Recognizing that the "healthcare sector perspective" can be too limited in some situations, the National Institute of Health and Care Excellence (NICE), Institute for Clinical and Economic Review (ICER), and the U.S. Second Panel on Cost-Effectiveness in Health and Medicine all recommend a "societal" perspective in "reference case" cost-effectiveness analyses (CEAs). Although costs of informal caregiving are sometimes included in the CEAs of Alzheimer's Disease (AD) drugs, the benefits and disutility to family members, referred to as "family spillovers" by the U.S. Second Panel, are usually omitted. We estimate that the aggregate cost of family spillovers could be substantial in the USA—on the order of USD 57 billion or over 10 percent of the total economic burden of AD in 2020. Incorporation of family spillovers in AD value frameworks and HTAs is important for comprehensively defining, rewarding, and providing high-value care in AD.
- Publication
International Journal of Technology Assessment in Health Care, 2021, Vol 38, Issue 1, p1
- ISSN
0266-4623
- Publication type
Article
- DOI
10.1017/S0266462321000593